Provided is an analysis apparatus having a control part having a preparatory action setting part for determination of whether the first and second controls are performed or the third and fourth controls are performed. The first control sets a sleep-planned part to a sleep state at a first time point when the state of non-use of the analysis apparatus has lasted for a predetermined time length, and then causes performance of a preparatory action by a first predetermined part; the second control resumes the operation of the analysis apparatus when a command signal to resume the operation is received; the third control places a sleep-planned part in a sleep state at a second time point when the state of non-use has lasted for a time length; and the fourth control causes a preparatory action of a second predetermined part to resume operation.

A diagnostic device which enables measurement of fibrinogen concentration in a blood sample. The device comprises; a wettable testing substrate including viewing indicators which allow determination of a status of a test. The substrate has a first end and second end and intermediate therebetween a flow receiving zone, a flow path zone and a reaction zone; the reaction zone pre charged with at least one reagent. A blood sample to be tested is deposited near or in either of said flow receiving zone or said reaction zone, the sample reacting with the reagents inducing clotting of the sample. Water added to a dye added to said reaction zone, advances a distance along said substrate. The distance travelled along the substrate by the dye and through the sample is indicative of a measure of concentration of fibrinogen in said blood sample under test.

A method for establishing an obese ferret model by feeding a ferret with a diet having at least 25% of carbohydrate content for a period of time to provide the obese ferret model is disclosed as is a method of using said model to screen a substance for treating a respiratory infection.

The present invention provides an anti-APOA4 monoclonal antibody or an antibody fragment thereof capable of accurately measuring apolipoprotein A-IV (APOA4) in a specimen, a measurement method for immunologically measuring APOA4 using the antibody or the antibody fragment thereof, and a kit for measuring APOA4 containing the antibody or the antibody fragment thereof.

The invention relates to isolation of adipocyte-derived exosomes from a biological sample, as well as methods, compositions and kits for detecting an obesity-related disorder, for detecting risk of having an obesity-related disorder, for screening or identifying a therapy for an obesity-related disorder, for screening or identifying a therapeutic agent for an obesity-related disorder, and for treating or preventing an obesity-related disorder.

The invention is directed to a method of livestock breeding, meat production and marketing, histology, and genetics using a biopsy sample from a non-meat location of the livestock to provide information about the meat quality of the livestock.

Multiparametric analysis is performed at the single cell level of biological samples obtained from an individual during pregnancy to obtain a determination of changes in immune cell subsets, which changes include, without limitation, altered activation states of proteins involved in signaling pathways. Changes occur in signaling pathways of these immune cells that are predictive of propensity to develop preeclampsia in the pregnancy.

The present disclosure provides methods and compositions for treatment, screening, diagnosis and prognosis of hepatocellular carcinoma with extrahepatic metastasis. Provided herein are methods and compositions for treatment, screening, diagnosis and prognosis of metastatic cancers. Also provided are antibodies and compositions for the treatment of cancers. Provided herein is therapeutic target for the treatment of cancers or as a marker for cancers. In particular, the protein represents a biological target against which affinity molecules including therapeutic antibodies, or other pharmaceutical agents, can be made. The disclosure also relates to the use of such affinity molecules for the treatment and/or diagnosis of cancers.

The disclosure provides methods for the diagnosis of Huntington's disease. In some embodiments, the method comprises detecting one or more repeat associated non-ATG (RAN) proteins in a biological sample.

A method of non-invasively diagnosing and treating a cancer characterized by high surface phosphatidylserine (PS) expression in a subject in need thereof is provided, the method including: obtaining a liquid biological sample from the subject; detecting a presence of cancer-secreted soluble phosphorylated Heat shock protein-70 (Hsp70) in the liquid biological sample; diagnosing the subject with a cancer characterized by high surface PS expression when cancer-secreted soluble phosphorylated Hsp70 is present in the liquid biological sample; and administering an anti-cancer therapy targeted to high surface PS expressing-cancers to the diagnosed subject. Also provided is a method for monitoring therapeutic efficacy of a treatment in a subject with a cancer characterized by high surface PS expression.